Trial Profile
Identification of dose escalation adalimumab, golimumab, infliximab or vedolizumab therapy in patients with inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- 03 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research